Fig. 1: Selection of pre-menopausal patients with HR+ ILC from an institutional database of 835 ILC cases. | npj Breast Cancer

Fig. 1: Selection of pre-menopausal patients with HR+ ILC from an institutional database of 835 ILC cases.

From: Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

Fig. 1

A Flow diagram depicting study population selection from an institutional invasive lobular carcinoma database. B Breakdown of type of adjuvant endocrine therapy received throughout treatment. ER estrogen receptor, PR progesterone receptor, SERM selective estrogen receptor modulator, AI aromatase inhibitor, OFS ovarian function suppression.

Back to article page